Toronto Dominion Bank’s Briacell Therapeutics BCTX Stock Holding History

Toronto Dominion Bank’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Hold	0	–	-$206	–	1611
2023 Q3	–	Hold	0	–	–	–	1589
2022 Q3	–	Sell	-1	Closed	-$1K	–	1558
2022 Q2	$1K	Buy	+1	New	+$988	﹤0.01%	1237
2022 Q1	–	Hold	0	–	–	–	1445
2021 Q4	–	Hold	0	–	–	–	1527
2021 Q3	–	Sell	-6	Closed	-$5.52K	–	1377
2021 Q2	$5K	Buy	+6	New	+$3.74K	﹤0.01%	1276
2021 Q1	–	Hold	0	–	–	–	1454

Other funds holding BCTX

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

STA

Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

OBWG

Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return

Toronto Dominion Bank's BCTX Position: Q4 2023 in Review

Toronto Dominion Bank held its Briacell Therapeutics (BCTX) position steady in Q4 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

Toronto Dominion Bank first reported a position in BCTX in Q2 2021 and has held it in 2 quarters since. The position peaked at $5K in Q2 2021. 23 funds tracked by Wall St. Rank hold BCTX as of Q4 2023.

Toronto Dominion Bank held 0 shares of Briacell Therapeutics worth $0 as of Q4 2023.
Toronto Dominion Bank left its Briacell Therapeutics share count unchanged in Q4 2023.
Briacell Therapeutics made up ﹤0.01% of Toronto Dominion Bank's portfolio in Q4 2023, its #1611 holding.
Toronto Dominion Bank first reported a position in Briacell Therapeutics in Q2 2021 and has held it in 2 quarters since.
Toronto Dominion Bank's Briacell Therapeutics position peaked at $5K in Q2 2021.
23 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2023.

Based on Toronto Dominion Bank's 13F filing for Q4 2023, filed 13 Feb 2024.